# PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)

> **NCT00703885** · PHASE4 · COMPLETED · sponsor: **University of California, San Diego** · enrollment: 16 (actual)

## Conditions studied

- Anxiety Disorders

## Interventions

- **DRUG:** 0.25 mg alprazolam
- **DRUG:** 1.0 mg alprazolam
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00703885
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00703885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00703885, "PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00703885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*